Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) plus radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM). Reardon, D. A., Kaley, T., Dietrich, J., Clarke, J., Dunn, G., Lim, M., Cloughesy, T., Gan, H., Park, A. J., Schwarzenberger, P., Ricciardi, T., Macri, M. J., Ryan, A., Venhaus, R. AMER SOC CLINICAL ONCOLOGY. 2019
View details for DOI 10.1200/JCO.2019.37.15_suppl.2032
View details for Web of Science ID 000487345804414